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Background: Limited studies have suggested that inflammatory biomarkers play a role in the initiation and
progression of atherosclerosis in diabetic patients. This study assesses the effect of inflammatory biomarkers:
fibrinogen and C-reactive protein (C-RP) on the progression of peripheral arterial disease (PAD) in type 2 diabetic
(T2D) patients.
Methods: Sixty two patients with T2D and PAD (mean age 60.28 ± 27 years and diabetes duration of 8.58 ± 6.17 years)
were enrolled in a cohort prospective study of 36 months. Ankle-brachial index (ABI) was measured in all patients at
baseline and after 36 months. Multiple linear regression analysis was used to determine the predictivity of variables for
fibrinogen, C-RP, plasma lipid fractions, fasting plasma glucose, Body Mass Index (BMI), duration of diabetes status and
the age on changes in ABI value.
Results: Linear regression analysis defined F as a predictor for endpoint value of ABI (β = 0.469, p = 0.007). Value of
C-RP determinates change of minimal value of ABI (β = 0.449, p = 0.037) and change of mean ABI per year (β = 0.442,
p = 0.025).
Conclusion: Our data indicate that plasma determination of fibrinogen and C-RP might have a clinical implication in
defining the process of progression of PAD in T2D population.
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Previous studies have found accelerated atherosclerosis
and increased risk of vascular disease in diabetic patients
[1,2]. Risk factors such as hyperglycaemia and glucose
intolerance, hyperlipidaemia, obesity and hypertension
have been established as risk factors for diabetic vascular
disease [3,4].
However, very little is known about the potentially
unique features of this inflammatory process in diabetic
vascular disease. Some studies have suggested that the
inflammatory biomarkers, C-RP and fibrinogen, play a
role in initiation, aggravation of the classical pathways
and progression of atherosclerosis in diabetic patients
[5-7]. These biomarkers are more closely related with* Correspondence: lily.stojanovska@vu.edu.au
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reproduction in any medium, provided the orthe metabolic syndrome and insulin resistance compared
with cytokines, and they influence the onset of potential
cardiovascular events [8].
Hyperfibrinogenemia, a condition of elevated level of
fibrinogen in the blood, is found more frequently in dia-
betic patients with manifested peripheral arterial disease
(PAD) and more severe coronary artery disease (CAD)
[9]. High levels of C-RP have been found in advanced
stages of atherosclerosis in diabetic patients, especially
in those with high level of HbA1C and high concentra-
tion of advanced glycated proteins [10]. The purpose of
this study was to determinate the influence of inflamma-
tory biomarkers: fibrinogen and C-RP on progression of
PAD in type 2 diabetic (T2D) patients as measured with
changes in ABI values.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Sixty seven patients with T2D and PAD were enrolled in a
cohort prospective study between 2005 and 2008. Five
patients were excluded from the study, while the
remaining 62 patients that met the inclusion criteria were
followed-up for 36 months. The study was conducted at
the vascular laboratory at University Cardiology Clinic
Skopje. The study was carried out according to the
Helsinki declaration and was approved by the University
Clinic Ethics Committee, Skopje.
Type 2 diabetes was defined based on the criteria of the
International Diabetes Federation. Patients with PAD,
stage Fontaine I, with an established value of ABI < 0. 9
met the inclusion criteria for the study. Those with
advanced PAD stage and with high, pathological ABI
values, as well with acute inflammatory state (diabetic foot
infection, cold, pneumonia) were excluded from the study.
In all patients, we measured at baseline and after 36
months, at the completion of the study the ABI value,
using a continuous wave Doppler (Hunleigh Healtcare,
Cardiff, UK) to determine the lowest ABI values (ratio of
ankle to brachial pressure). ABI was measured by vascular
physicians with the same person being involved through-
out the study. Inter-observer variability was up to 6%,
measured previously. Mean values were calculated from
the average of two measurements. Following the endpoint
measurement of the ABI, a change in ABI was also
calculated.
Laboratory tests were conducted at the University Insti-
tute for Clinical Biochemistry. Fibrinogen and C-RP were
determined using the BNII nephelometer (N High-
Sensitivity C-RP and N Antiserum to Human Fibrinogen;Model B Std.
C-RP Constant 32.673 2
DM.duration -0.652
BMI -1.134
ABI.min 54.120 2
Fibrinogen Constant 13.027
Non.HDL 0.706
Figure 1 Multiple linear regression analysis for factors for C-RP and fiDade Behring). Serum levels of the following laboratory
tests were measured at baseline and at 36 weeks in all
patients: total cholesterol (enzymatic methods-in the pres-
ence of cholesterol oxidize), triglycerides (in the presence
of glycerokinase), and the HDL fraction by direct method.
Automatic analyzer Coba Integra 400/700 (ROCHE
Diagnostics) was used. The LDL fraction was evaluated
using the Friedewald formula. Non-HDL cholesterol was
determinate as a value of total cholesterol minus HDL
cholesterol. Fasting plasma glucose concentration was
evaluated using the enzymatic-photometric method, in
the presence of glucoso-dehydrogenase. All analyses were
done according recommendation of International Feder-
ation of Clinical Chemistry and Laboratory Medicine.
Multiple linear regression analysis was used to define
continuous variables with predictive value for the ABI,
when adjusted for systolic blood pressure, BMI index,
diabetes duration, age, blood glucose, plasma lipid levels
(total, LDL-, HDL- cholesterol), C-RP and fibrinogen.
The data is expressed as mean ± SD.
Results
Sixty-two participants were included for analysis, com-
prising 39 males and 23 females. The baseline
characteristics for the study population were as follows:
mean age of 60.28 ± 27 years; mean diabetes duration of
8.58 ± 6.17 years, and overweight status by BMI (mean
BMI 28.7 + 4 kg/m2).
At baseline the mean fasting plasma glucose of the
group was 8.5 ± 2.4 mmol/L, mean plasma fibrinogen
level was 4.12 ± 0.85 g/L and had a mean of C-RP of
5.69 ± 1.92 mmol/L. Measurements of the lipid profile at Error Beta t Sig 
9.118 1.122 0.299
0.226 -0.696 -2.881 0.024
0.476 -0,565 -2.381 0.049
2.970 3.477 2.356 0.050
3.564 3.656 0.004
0.277 1.093 2.548 0.027
brinogen.
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LDL-cholesterol of 3.3 ± 0.9 mmol/L, and HDL-cholesterol
of 1.0 ± 0.4 mmol/L.
Of all the patients 98.4% received acetyl salicylic acid,
while 85.4% received statins. Furthermore, 59.6% of the
patients were treated with oral anti-diabetics and 41.4%
of them with insulin.
The measurements of the ABI indexes at baseline
were: ABIx = 0.83 ± 0.04 (mean) and ABImin = 0.75 +
0.07 (lowest), while following the 36 months we found
ABIx = 0.45 ± 0.05 and ABImin = 0.48 ± 0.06. Significant
changes of minimal value of ABI (dABImin = 0.38 ± 3.1)
and mean ABI (dABIx = 0.27 ± 0.21) were found. No
gender differences were found according ABI indexes.
Multivariate analysis showed that F value has been
determined with non HDL - cholesterol (β = 1.093, p =
0.027). Linear regression analysis defined fibrinogen as a
predictor for minimal value of ABI, found at the comple-
tion of the study (β = 0.469, p = 0.007).Model B Std. E
ABImin Constant 2.639 1.
LD
L
.121 .
BMI 2.360E-02 .
FIBRIN -.196 .
dABImin Constant .632 1.
ABI.X 2.176 .
CRP 1.962E-02 .
dABIx/y Constant -.350 .
AGE 4.160E-03 .
ABI.X .732 .
ABI.MIN -.541 .
C-RP 5.140E-03 .
Figure 2 C-RP and Fibrinogen as factors for progression of ABI (multiThe value of C-RP was independently determined with
diabetes duration, BMI and minimal value of ABI,
according to the results of multiple linear regression
analysis. Fibrinogen was determinated with the value of
non HDL - cholesterol (Figure 1).
Linear regression analysis defined fibrinogen as pre-
dictor for minimal value of ABI, found at the end com-
pletion of the study (β = 0.469, p = 0.007). The value of
C-RP determinates the change of minimal value of ABI
(dABImin) and the change of mean ABI per year
(dABIx/y) (Figure 2).Discussion
Patients with T2D often present with hypercoagulability,
which may be related to changes in inflammatory
biomarkers [11]. Patients with vascular disease and T2D
presented higher values of inflammation markers when
compared with patients without vascular disease [12]. Inrror Beta t Sig
094 2.412 .024
057 .386 2.138 .042
009 .436 2.534 .018
067 -.469 -2.926 .007
049 .603 .552
963 2.833 2.261 .033
009 .449 2.210 .037
254 -1.376 .181
002 .460 2.441 .022
233 3.579 3.140 .004
204 -2.988 -2.656 .014
002 .442 2.389 .025
ple linear regression analysis).
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significantly elevated.
Impact of fibrinogen
Fibrinogen and non-HDL cholesterol have synergistic
effects, as factors accelerating the progression of carotid
atherosclerosis [13]. Fibrinogen increases atherogenic
dislipidaemia in diabetic patients. Fibrates act synergistic-
ally in the regulation of dispilidaemia, reduction in fibrino-
gen, triglycerides, LDL and non HDL- cholesterol [14,15].
Increased fibrinogen, as an inflammatory, haemostatic
component, is present in diabetic patients, who are on
oral hypoglycaemic as well as on insulin therapy [16].
Studies have shown that fibrinogen is associated with
diabetes regulation, age, hypertension and components
of the metabolic syndrome [17,18].
Increased fibrinogen levels are often present in dia-
betic patients with PAD, and there is a correlation with
fibrinogen values and angiographic extent of the disease
[19,20]. Fibrinogen compared with C-RP might be
closely associated with diabetic vascular disease [21].
The minimal value of ABI, found at the completion of our
study correlates with the levels of fibrinogen measured at
baseline. Fibrinogen values over 3.5 g/L have been shown
previously to be an independent marker for progressive
cardiac events in diabetic patients [22]. Our results show
that increased fibrinogen level of >4 g/L is a risk factor for
progression of PAD, as assessed by a decrease of ABI value.
Some studies have implied that the process of
inflamation is the bridge between metabolic syndrome,
insulin resistance and atherosclerosis [23]. As the latter
causes are highly prevalent in diabetic patients, it is
expected to observe a presence of significant inflamation
in diabetic patients. Inflamation influences development
of prediabetic phase in type 2 diabetes mellitus [24].
C-RP in diabetic vascular disease
According to our results the C-RP value is independ-
ently connected with diabetes duration, BMI and ABI
index. Obesity is a major risk factor, correlated with C-
RP in populations with metabolic syndrome and/or T2D
(ADOPT) [25,26]. Follow up studies in diabetic patients
with coronary and carotid atherosclerosis, have shown
that advanced atherosclerosis in T2D is connected with
increased C-RP values and increased concentrations of
advanced glycosylation products [27]. This high cardio-
vascular risk may be due to a combination of non-clas-
sical risk factors associated with insulin resistance, e.g.
inflammation, hyperinsulinemia, oxidative stress, and
hypercoagulability, together with the separate compo-
nents of metabolic syndrome [28,29].
Serum C-RP level was independently associated with
PAD in T2D in a cross-sectional study by Yu and
associates [30]. Our longitudinal study has shown thatC-RP is an independent factor for dynamic change of
minimal and mean values of ABI.
Therapeutic possibilities
Potential applications of these observations have im-
plications in clinical management of T2D patients with
PAD. Previous studies imply that measuring inflammatory
biomarkers may improve the definition of cerebrovascular
risk profile in patients with type 2 diabetes [31]. Improve-
ment of inflammatory state in diabetic population is
associated with improvement of glyco-metabolic control.
The use of insulin, metformin, sulfonylurea, thiazolindiones,
and especially high doses of statins, according to the above
studies, lead to reduction in C-RP and other inflammatory
biomarker values in patients with T2D [32-36]. The use of
statins, fibrates and glitazones although favorable, are not
sufficient to cause the progression of diabetic vascular
disease [37,38].
Limitations
ABI is defined as reliable marker for definition PAD,
despite numerous factors that influence its value [39].
We measured progression of peripheral atherosclerosis
using this index.
Our results are of a preliminary nature and as such this
study has limitations due to its small sample size. Larger
prospective studies in the future are therefore necessary.
Conclusion
Our results indicate that fibrinogen and C-RP independ-
ently influence the progression of peripheral atheroscler-
osis in T2D patients. Plasma determination of these
inflammatory biomarkers might have an implication in
predicting the clinical course of peripheral arterial dis-
ease in T2D population.
Abbreviations
T2D: Type 2 Diabetes; PAD: Peripheral arterial disease; ABI: Ankle-brachial
index; C-RP: C-Reactive protein.
Competing interests
The authors declare that they have no competing interests.
Authors’ contribution
MB: design and results of study. GB: contributed to biomarker analysis and
related discussion. LS: revised the manuscript critically for important
intellectual content. All authors read and approved the final manuscript.
Acknowledgements
The authors wish to thank the participants in the study, and acknowledge
the contribution of Mrs Kristina Nelson, Victoria University, for her editorial
assistance of this paper and Mrs Saska Domazetovska, University Clinic for
Clinical Biochemistry for her assistance in the part of laboratory methods.
Author details
1Medical Faculty, University Cardiology Clinic, Skopje, Macedonia. 2Institute
for Public Health of R. Macedonia, Skopje, Macedonia. 3College of Health and
Biomedicine, Victoria University, Melbourne, Australia. 4School of Biomedical
and Health Sciences, Victoria University, PO Box 14428, Melbourne, Vic 8001,
Australia.
Bosevski et al. Cardiovascular Diabetology 2013, 12:29 Page 5 of 6
http://www.cardiab.com/content/12/1/29Received: 23 January 2013 Accepted: 27 January 2013
Published: 1 February 2013
References
1. Raggi P, Cooil B, Ratti C, Callister TQ, Budoff M: Progression of coronary
artery calcium and occurrence of myocardial infarction in patients with
and without diabetes mellitus. Hypertension 2005, 46(1):238–243.
2. Alvarsson A, Sandgren B, Wendel C, Alvarsson M, Brismar K: A retrospective
analysis of amputation rates in diabetic patients: can lower extremity
amputations be further prevented? Cardiovasc Diabetol 2012, 11:18.
3. Wagenknecht LE, D’Agostino R Jr, Savage PJ, O’Leary DH, Saad MF, Haffner
SM: Duration of diabetes and carotid wall thickness. The Insulin
Resistance Atherosclerosis Study (IRAS). Stroke 1997, 28:999–1005.
4. Sander D, Schulze-Horn C, Bickel H, Gnahn H, Bartels E, Conrad B:
Combined effects of hemoglobin A1c and C-reactive protein on the
progression of subclinical carotid atherosclerosis: the INVADE study.
Stroke 2006, 37(2):351–357.
5. Ross R: Atherosclerosis: an inflammatory disease. N Engl J Med 1999,
314:115–126.
6. Hayden M, Tyagi S: Intimal redox stress: Accelerated atherosclerosis in
metabolic syndrome and type 2 diabetes mellitus, Atheroscleropathy.
Cardiovasc Diabetol 2002, 1(3):1–27.
7. Poulsen MK, Nybo M, Dahl J, Hosbond S, Poulsen TS, Johansen A, Høilund-
Carlsen PF, Beck-Nielsen H, Rasmussen LM, Henriksen JE: Plasma
osteoprotegerin is related to carotid and peripheral arterial disease, but
not to myocardial ischemia in type 2 diabetes mellitus. Cardiovasc
Diabetol 2011, 10:76.
8. Goldberg RB: Cytokine and cytokine-like inflammation markers,
endothelial dysfunction, and imbalanced coagulation in development of
diabetes and its complications. J Clin Endocrinol Metab 2009,
94(3):3171–3182.
9. O'Neal DN, Dragicevic G, Rowley KG, Ansari MZ, Balazs N, Jenkins A, et al: A
cross-sectional study of the effects of type 2 diabetes and other
cardiovascular risk factors on structure and function of nonstenotic
arteries of the lower limb. Diabetes Care 2003, 26(1):199–205.
10. Tan KC, Chow WS, Tam S, Bucala R, Betteridge J: Association between
acute-phase reactants and advanced glycation end products in type 2
diabetes. Diabetes Care 2004, 27(1):223–228.
11. Beijers HJ, Ferreira I, Spronk HM, Bravenboer B, Dekker JM, Nijpels G, Ten
Cate H, Stehouwer CD: Impaired glucose metabolism and type 2 diabetes
are associated with hypercoagulability: potential role of central adiposity
and low-grade inflammation -The Hoorn Study. Thromb Res 2012,
129(5):557–562.
12. Akalin A, Alatas O, Colak O: Relation of plasma homocysteine levels to
atherosclerotic vascular disease and inflammation markers in type 2
diabetic patients. Eur J Endocrinol 2008, 158:47–52.
13. Rizzo M, Corrado E, Coppola G, Muratori I, Novo G, Novo S: Prediction of
cardio- and cerebro-vascular events in patients with subclinical carotid
atherosclerosis and low HDL-cholesterol. Atherosclerosis 2008,
56(1):32–40.
14. Mertens I, Lemieux I, Verrijken A, Després JP, Van Gaal LF: PAI-1 activity, but
not fibrinogen or von Willebrand factor, is inversely related to LDL particle
size in type 2 diabetes. Diabetes Metab Res Rev 2008, 24(2):141–147.
15. Bianchi C, Penno G, Malloggi L, Barontini R, Corfini M, Giovannitti MG, et al:
Non-traditional markers of atherosclerosis potentiate the risk of coronary
heart disease in patients with type 2 diabetes and metabolic syndrome.
Nutr Metab Cardiovasc Dis 2008, 18(1):31–38.
16. Wu TJ, Ou HY, Chou CW, Hsiao SH, Lin CY, Kao PC: Decrease in
inflammatory cardiovascular risk markers in hyperlipidemic diabetic
patients treated with fenofibrate. Ann Clin Lab Sci 2007, 37(2):158–166.
17. Knöbl P, Schernthaner G, Schnack C, Pietschmann P, Proidl S, Prager R, et al:
Haemostatic abnormalities persist despite glycaemic improvement by
insulin therapy in lean type 2 diabetic patients. Thromb Haemost 1994,
71(6):692–697.
18. Bruno G, Cavallo-Perin P, Bargero G, Borra M, D'Errico N, Macchia G, et al:
Hyperfibrinogenemia and metabolic syndrome in type 2 diabetes: a
population-based study. Diabetes Metab Res Rev 2001,
17(2):124–130.
19. Lam TH, Liu LJ, Janus ED, Lam KS, Hedley AJ: Hong Kong Cardiovascular
Risk Factor Prevalence Study Steering Committee. Fibrinogen, other
cardiovascular risk factors and diabetes mellitus in Hong Kong: acommunity with high prevalence of Type 2 diabetes mellitus and
impaired glucose tolerance. Diabet Med 2000, 17(11):798–806.
20. Bosevski M, Borozanov V, Peovska I, Georgievska-Ismail L: Endothelial
dysfunction correlates with plasma fibrinogen and HDL cholesterol in
type 2 diabetic patients with coronary artery disease. Bratisl Lek Listy
2007, 108(7):297–300.
21. Takebayashi K, Suetsugu M, Matsutomo R, Wakabayashi S, Aso Y, Inukai T:
Correlation of high-sensitivity C-reactive protein and plasma fibrinogen
with individual complications in patients with type 2 diabetes. South
Med J 2006, 99:23–27.
22. Hutajulu SH, Kurnianda J, Purwanto I, Asdie RH, Wiyono P, Asdie AH:
Fibrinogen and plasminogen activator inhibitor-1 level in peripheral arterial
disease of type 2 diabetes patients. Acta Med Indones 2006, 38(3):126–129.
23. Schmechel H, Beiküfner P, Panzram G: Longitudinal studies on the
prognostic significance of plasma fibrinogen in diabetes mellitus.
Z Gesamte Inn Med 1984, 39(18):453–457.
24. Ziegler D: Type 2 diabetes as an inflammatory cardiovascular disorder.
Curr Mol Med 2005, 5(3):309–322.
25. Nesto R: C-reactive protein, its role in inflammation, Type 2 diabetes and
cardiovascular disease, and the effects of insulin-sensitizing treatment
with thiazolidines. Diabet Med 2004, 21(8):810–817.
26. Kahn SE, Zinman B, Haffner SM, O'Neill MC, Kravitz BG, Yu D, et al: ADOPT
Study Group. Obesity is a major determinant of the association of C-
reactive protein levels and the metabolic syndrome in type 2 diabetes.
Diabetes 2006, 55(8):2357–2364.
27. Zaciragić A, Huskić J, Hadzović-Dzuvo A, Valjevac A, Avdagić N, Mulabegović
N: Serum C-reactive protein concentration and measures of adiposity in
patients with type 2 diabetes mellitus. Bosn J Basic Med Sci 2007,
7(4):322–327.
28. Moussavi N, Renier G, Roussin A, Mamputu JC, Buithieu J, Serri O: Lack of
concordance between plasma markers of cardiovascular risk and intima-
media thickness in patients with type 2 diabetes. Diabetes Obes Metab
2004, 6(1):69–77.
29. Verhagen SN, Wassink AM, van der Graaf Y, Gorter PM, Visseren FL, SMART
Study Group: Insulin resistance increases the occurrence of new
cardiovascular events in patients with manifest arterial disease without
known diabetes. The SMART study. Cardiovasc Diabetol 2011, 10:100.
30. Yu HI, Sheu WH, Song YM, Liu HC, Lee WJ, Chen YT: C-reactive protein and
risk factors for peripheral vascular disease in subjects with Type 2
diabetes mellitus. Diabet Med 2004, 21(4):336–341.
31. Kadoglou NP, Avgerinos ED, Liapis CD: An update on markers of carotid
atherosclerosis in patients with Type 2 diabetes. Biomark Med 2010,
4:601–609.
32. Viberti G, Kahn SE, Greene DA, Herman WH, Zinman B, Holman RR, et al: A
diabetes outcome progression trial (ADOPT): an international
multicenter study of the comparative efficacy of rosiglitazone, glyburide,
and metformin in recently diagnosed type 2 diabetes. Diabetes Care
2002, 25(10):1737–1743.
33. Derosa G, Fogari E, Cicero AF, D'Angelo A, Ciccarelli L, Piccinni MN, et al:
Blood pressure control and inflammatory markers in type 2 diabetic
patients treated with pioglitazone or rosiglitazone and metformin.
Hypertens Res 2007, 30(5):387–394.
34. Sobel BE, Hardison RM, Genuth S, Brooks MM, McBane RD 3rd, Schneider
DJ, Pratley RE, Huber K, Wolk R, Krishnaswami A, Frye RL, for the BARI 2D
Investigators: Profibrinolytic, Antithrombotic, and Antiinflammatory
Effects of an Insulin-Sensitizing Strategy in Patients in the Bypass
Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial.
Circulation 2011, 124(6):695–703.
35. Joya-Galeana J, Fernandez M, Cervera A, Reyna S, Ghosh S, Triplitt C, Musi N,
DeFronzo RA, Cersosimo E: Effects of insulin and oral anti-diabetic agents
on glucose metabolism, vascular dysfunction and skeletal muscle
inflammation in type 2 diabetic subjects. Diabetes Metab Res Rev 2011,
27(4):373–382.
36. Forst T, Wilhelm B, Pfützner A, Fuchs W, Lehmann U, Schaper F, et al:
Investigation of the vascular and pleiotropic effects of atorvastatin and
pioglitazone in a population at high cardiovascular risk. Diabetes Vasc Dis
Res 2008, 5:298–303.
37. Wägner AM, Sánchez-Quesada JL, Benítez S, Bancells C, Ordóñez-Llanos J,
Pérez A: Effect of statin and fibrate treatment on inflammation in type 2
diabetes. A randomized, cross-over study. Diabetes Res Clin Pract 2011,
93(1):e25–e28.
Bosevski et al. Cardiovascular Diabetology 2013, 12:29 Page 6 of 6
http://www.cardiab.com/content/12/1/2938. Krysiak R, Gdula-Dymek A, Okopien B: Effect of simvastatin and fenofibrate
on cytokine release and systemic inflammation in type 2 diabetes
mellitus with mixed dyslipidemia. Am J Cardiol 2011, 107(7):1010–1018.e1.
39. Xiao L, Huang DS, Tong JJ, Shen J: Efficacy of endoluminal interventional
therapy in diabetic peripheral arterial occlusive disease: a retrospective
trial. Cardiovasc Diabetol 2012, 11:17.
doi:10.1186/1475-2840-12-29
Cite this article as: Bosevski et al.: Influence of fibrinogen and C-RP on
progression of peripheral arterial disease in type 2 diabetes:
a preliminary report. Cardiovascular Diabetology 2013 12:29.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
